HUE053429T2 - (S)-3-amino-4-(difluor-metilenil)-ciklopent-l-én-l-karbonsav és rokon vegyületek, mint gaba-aminotranszferáz-inaktivátorok epilepszia, függõség és hepatocelluláris karcinóma kezelésében - Google Patents
(S)-3-amino-4-(difluor-metilenil)-ciklopent-l-én-l-karbonsav és rokon vegyületek, mint gaba-aminotranszferáz-inaktivátorok epilepszia, függõség és hepatocelluláris karcinóma kezelésébenInfo
- Publication number
- HUE053429T2 HUE053429T2 HUE16854531A HUE16854531A HUE053429T2 HU E053429 T2 HUE053429 T2 HU E053429T2 HU E16854531 A HUE16854531 A HU E16854531A HU E16854531 A HUE16854531 A HU E16854531A HU E053429 T2 HUE053429 T2 HU E053429T2
- Authority
- HU
- Hungary
- Prior art keywords
- difluoromethylenyl
- cyclopent
- gaba
- epilepsy
- ene
- Prior art date
Links
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 title 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 title 1
- FBLNZOCTNRXJQD-YFKPBYRVSA-N N[C@H]1C=C(CC1=C(F)F)C(O)=O Chemical compound N[C@H]1C=C(CC1=C(F)F)C(O)=O FBLNZOCTNRXJQD-YFKPBYRVSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010015037 epilepsy Diseases 0.000 title 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 title 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title 1
- 230000000937 inactivator Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239330P | 2015-10-09 | 2015-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE053429T2 true HUE053429T2 (hu) | 2021-07-28 |
Family
ID=58488679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16854531A HUE053429T2 (hu) | 2015-10-09 | 2016-10-10 | (S)-3-amino-4-(difluor-metilenil)-ciklopent-l-én-l-karbonsav és rokon vegyületek, mint gaba-aminotranszferáz-inaktivátorok epilepszia, függõség és hepatocelluláris karcinóma kezelésében |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9670141B2 (enExample) |
| EP (1) | EP3341355B1 (enExample) |
| JP (1) | JP6841821B2 (enExample) |
| KR (1) | KR102745965B1 (enExample) |
| CN (1) | CN108137484B (enExample) |
| AU (1) | AU2016334396B2 (enExample) |
| BR (1) | BR112018007026B1 (enExample) |
| CA (1) | CA3001330A1 (enExample) |
| CL (1) | CL2018000914A1 (enExample) |
| CO (1) | CO2018003828A2 (enExample) |
| DK (1) | DK3341355T3 (enExample) |
| ES (1) | ES2825349T3 (enExample) |
| HU (1) | HUE053429T2 (enExample) |
| IL (1) | IL258516A (enExample) |
| LT (1) | LT3341355T (enExample) |
| MX (1) | MX380592B (enExample) |
| PE (1) | PE20190349A1 (enExample) |
| PL (1) | PL3341355T3 (enExample) |
| PT (1) | PT3341355T (enExample) |
| WO (1) | WO2017062942A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59111B1 (sr) | 2014-08-21 | 2019-09-30 | Boehringer Ingelheim Int | Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori |
| US9670141B2 (en) * | 2015-10-09 | 2017-06-06 | Northwestern University | (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma |
| KR20240158360A (ko) | 2015-10-09 | 2024-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체 |
| KR20240110989A (ko) * | 2017-02-08 | 2024-07-16 | 오비드 테라퓨틱스 인크. | 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들 |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| WO2019157273A1 (en) | 2018-02-08 | 2019-08-15 | Ovid Therapeutics Inc. | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| AU2019243586A1 (en) * | 2018-03-29 | 2020-10-15 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
| US10822301B2 (en) * | 2018-04-12 | 2020-11-03 | Northwestern University | 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase |
| PL3784649T3 (pl) * | 2018-05-25 | 2024-10-14 | Northwestern University | Proces syntezy kwasu (s)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowego |
| MX2020013290A (es) | 2018-06-07 | 2021-04-29 | Ovid Therapeutics Inc | Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. |
| WO2020176511A1 (en) | 2019-02-25 | 2020-09-03 | Northwestern University | Analogs of 3-amino-4-(propan-2-ylidene) cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity |
| WO2020206234A1 (en) | 2019-04-03 | 2020-10-08 | Northwestern University | 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase |
| CN110935495B (zh) * | 2019-11-29 | 2021-02-23 | 中国科学院电子学研究所 | Gaba和电生理微纳同步传感检测芯片及其制备方法 |
| US11993569B2 (en) | 2020-01-23 | 2024-05-28 | Northwestern University | 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases |
| EP4301724A4 (en) * | 2021-03-03 | 2025-05-28 | Northwestern University | (S)-3-AMINO-4,4-DIHALOCYCLOPENT-1-CARBOXYLIC ACID AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE |
| IL317808A (en) * | 2022-07-06 | 2025-02-01 | Ovid Therapeutics Inc | Use of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in cancer treatment |
| IL322801A (en) * | 2023-02-17 | 2025-10-01 | Ovid Therapeutics Inc | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis |
| WO2024173750A2 (en) * | 2023-02-17 | 2024-08-22 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent |
| AU2024221204A1 (en) * | 2023-02-17 | 2025-09-04 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
| US20240285562A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| IL177609A (en) * | 2006-08-21 | 2015-11-30 | Yaron Ilan | Use of gobacoline or its analogue to produce a drug to treat liver carcinoma |
| EP2542234A4 (en) * | 2010-02-25 | 2013-07-31 | Univ Northwestern | PROCESS FOR USE OF (1S, 3S -) - 3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANIC ACID |
| AR087700A1 (es) * | 2011-08-30 | 2014-04-09 | Gilead Sciences Inc | Inhibidores de aldh-2 en el tratamiento de adicciones |
| US9670141B2 (en) * | 2015-10-09 | 2017-06-06 | Northwestern University | (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma |
-
2016
- 2016-10-10 US US15/289,480 patent/US9670141B2/en active Active
- 2016-10-10 WO PCT/US2016/056245 patent/WO2017062942A2/en not_active Ceased
- 2016-10-10 KR KR1020187013228A patent/KR102745965B1/ko active Active
- 2016-10-10 ES ES16854531T patent/ES2825349T3/es active Active
- 2016-10-10 DK DK16854531.7T patent/DK3341355T3/da active
- 2016-10-10 HU HUE16854531A patent/HUE053429T2/hu unknown
- 2016-10-10 JP JP2018517734A patent/JP6841821B2/ja active Active
- 2016-10-10 CA CA3001330A patent/CA3001330A1/en active Pending
- 2016-10-10 MX MX2018004302A patent/MX380592B/es unknown
- 2016-10-10 BR BR112018007026-2A patent/BR112018007026B1/pt active IP Right Grant
- 2016-10-10 LT LTEP16854531.7T patent/LT3341355T/lt unknown
- 2016-10-10 PL PL16854531T patent/PL3341355T3/pl unknown
- 2016-10-10 PT PT168545317T patent/PT3341355T/pt unknown
- 2016-10-10 CN CN201680059069.9A patent/CN108137484B/zh active Active
- 2016-10-10 EP EP16854531.7A patent/EP3341355B1/en active Active
- 2016-10-10 PE PE2018000517A patent/PE20190349A1/es unknown
- 2016-10-10 AU AU2016334396A patent/AU2016334396B2/en active Active
-
2017
- 2017-05-04 US US15/586,730 patent/US9993449B2/en active Active
-
2018
- 2018-04-05 IL IL258516A patent/IL258516A/en active IP Right Grant
- 2018-04-09 CL CL2018000914A patent/CL2018000914A1/es unknown
- 2018-04-10 CO CONC2018/0003828A patent/CO2018003828A2/es unknown
- 2018-05-29 US US15/991,323 patent/US20180271816A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE053429T2 (hu) | (S)-3-amino-4-(difluor-metilenil)-ciklopent-l-én-l-karbonsav és rokon vegyületek, mint gaba-aminotranszferáz-inaktivátorok epilepszia, függõség és hepatocelluláris karcinóma kezelésében | |
| IL287848A (en) | Multispecific antigen binding molecules and their uses | |
| DK3334422T3 (da) | Anvendelse af cannabidiolsyre i behandling af epilepsi | |
| IL259133A (en) | Jamkaban combinations for the treatment of cardiovascular disease | |
| ZA201708039B (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
| IL254116B (en) | Treatment of pancreatitis | |
| HUE052095T2 (hu) | Keratin kezelési készítmények és eljárások | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| IL248538B (en) | Vector viruses unrelated to the treatment of lysosomal storage disorders | |
| IL254251A0 (en) | Human fibrolamellar hepatocellular carcinomas (hfl-hccs) | |
| GB2538181B (en) | Improvements relating to the authentication of physical entities | |
| GB201513020D0 (en) | Radiation-curable compositions, membranes and the manufacture and use of such membranes | |
| LT3482761T (lt) | Kompozicijos, apimančios kromoglicino rūgštį, skirtos dermatito gydymui | |
| IL252774A0 (en) | A pharmaceutical preparation for the treatment of fungus | |
| GB201513543D0 (en) | Compositions for use in the treatment of diabetes | |
| Belsky | The Upside of Vulnerability | |
| FR3045273B1 (fr) | Piquet d'extremite | |
| TH1501007570A (th) | เจลที่มีส่วนผสมกรดเอลลาจิกที่มีฤทธิ์ยับยั้งการเพิ่มจำนวนของไวรัส | |
| TH1501004545A (th) | องค์ประกอบทางเภสัชกรรมที่มีเด็กซ์คีโตโพรเฟนและทรามาดอล | |
| TH1501004118A (th) | สารกระทำสำหรับการเพิ่มระดับความเข้มข้นของไนตริกออกไซด์ |